FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington,	DC	205/19
wasiiiiiqtoii,	D.C.	20349

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See	STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP
Instruction 1(b).	Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934

OMB APPROVAL OMB Number:

Estimated average burden hours per response: 0.5

					or S	ection	30(n) of the	investm	ient C	ompany Act	of 1940							
1. Name and Address of Reporting Person* LYONS GARY A				<u>NE</u>	2. Issuer Name and Ticker or Trading Symbol NEUROCRINE BIOSCIENCES INC [Check al		olicable)	g Person(s) to I			
(Last) (First) (Middle) 12780 EL CAMINO REAL				3. Dá	NBIX] 3. Date of Earliest Transaction (Month/Day/Year) 02/05/2018							Officer (give title below)			Other (specify below)			
(Street) SAN DIE			92130 Zip)		4. lf <i>i</i>	4. If Amendment, Date of Original Filed (Month/Day/Year)								vidual or Joint/Group Filing (Check Applicable Form filed by One Reporting Person Form filed by More than One Reporting Person				
		Tabl	e I - N	on-Deriv	ative	Seci	urities Ac	quire	d, Di	sposed o	f, or Be	enefici	ally O	νne	ed			
1. Title of Security (Instr. 3) 2. Transacti Date (Month/Day			Execution Date,		Transaction Code (Instr.		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and			nd 5) Secur Benef Owne		icially d Following	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership				
							Code	v	Amount	(A) or (D)	Price	т		ted action(s) 3 and 4)		(Instr. 4)		
Common	Stock			02/05/2	2018			S ⁽¹⁾		5,000	D	\$83.0	76 ⁽²⁾	^{76⁽²⁾} 267,066		D		
		Та	ble II				ities Acqu warrants,						-	ed				
1. Title of Derivative Security (Instr. 3)	erivative Conversion Date Execution Date, curity or Exercise (Month/Day/Year) if any		4. Transac Code (li 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		tion D	ate	7. Title a Amount Securitie Underlyi Derivativ Security and 4)	ount of urities Sec erlying (Ins vative urity (Instr. 3		ive y	9. Number of derivative Securities Beneficially Owned Following Reported Transaction (Instr. 4)	Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)			

Explanation of Responses:

1. The disposition reported in this Form 4 was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person at least 90 days prior to the transaction date in Box 2 above. Additionally, Issuer policy restricts the Reporting Person from amending, canceling, suspending or otherwise modifying any 10b5-1 trading plan subsequent to adoption of the plan.

Date

Exercisable

2. Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from \$81.52 to \$84.79. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.

Remarks:

/s/ Darin Lippoldt, Attorney-in-02/07/2018

Amount Number

Shares

Title

Fact

Expiration

Date

** Signature of Reporting Person

Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Code

(A) (D)

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.